• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc (TSX:CRDL)

1.420 +0.060 (+4.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,052
Open 1.410
Bid (Size) 1.390 (10)
Ask (Size) 1.420 (20)
Prev. Close 1.360
Today's Range 1.360 - 1.420
52wk Range 1.090 - 2.170
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
December 01, 2025
(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and 
Via PressReach
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
December 01, 2025
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac... 
Via Newsfile

Performance

YTD
+4.4%
+4.4%
1 Month
+2.2%
+2.2%
3 Month
-5.3%
-5.3%
6 Month
-27.9%
-27.9%
1 Year
-28.6%
-28.6%

More News

Read More
News headline image
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
August 06, 2025
Via PressReach
News headline image
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
April 16, 2025
Via Newsfile
News headline image
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart
February 20, 2025
Via Newsfile
News headline image
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
November 18, 2024
Via Newsfile
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
November 07, 2024
Via AB Newswire
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
October 22, 2024
Via AB Newswire
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
June 17, 2024
Via TheNewswire.com
News headline image
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
June 17, 2024
Via News Direct
News headline image
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
June 13, 2024
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
Via AB Newswire
Topics ETFs
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
Via TheNewswire.com
Topics ETFs
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
May 28, 2024
Via AB Newswire
News headline image
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
May 28, 2024
Via News Direct
News headline image
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
February 21, 2024
Via Newsfile
News headline image
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024
Via Newsfile
News headline image
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
November 01, 2023
Via Newsfile
News headline image
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects ↗
October 10, 2023
Via Benzinga
News headline image
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
October 10, 2023
Via Newsfile
Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
October 10, 2023
Via AB Newswire
Topics Stocks
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
October 02, 2023
Via AB Newswire
Topics Death
News headline image
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
September 19, 2023
Via Newsfile
News headline image
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
September 28, 2022
Via Newsfile
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Via FinancialNewsMedia

Frequently Asked Questions

Is Cardiol Therapeutics Inc publicly traded?
Yes, Cardiol Therapeutics Inc is publicly traded.
What exchange does Cardiol Therapeutics Inc trade on?
Cardiol Therapeutics Inc trades on the Toronto Stock Exchange
What is the ticker symbol for Cardiol Therapeutics Inc?
The ticker symbol for Cardiol Therapeutics Inc is CRDL on the Toronto Stock Exchange
What is the current price of Cardiol Therapeutics Inc?
The current price of Cardiol Therapeutics Inc is 1.420
When was Cardiol Therapeutics Inc last traded?
The last trade of Cardiol Therapeutics Inc was at 01/05/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap